FDG-PET/CT in the staging of local/regional metastases in breast cancer

Breast

Volumn 20, Issue 6, 2011, Pages 491-494

  Robertson, Ian J ^a   Hand, Fiona ^a   Kell, Malcolm R ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Breast cancer; FDG PET CT; Local regional metastases

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BREAST CANCER; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISTANT METASTASIS; ECHOGRAPHY; FALSE POSITIVE RESULT; HUMAN; INTERMETHOD COMPARISON; LOCAL METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PATIENT ASSESSMENT; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; REGIONAL METASTASIS; REVIEW; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY;

EID: 82955248110     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.07.002     Document Type: Review

References (25)

1. Key T.J., Verkasalo P.K., Banks E. Epidemiology of breast cancer. Lancet Oncol 2001, 2:133-140.
2. Rampaul R.S., Pinder S.E., Elston C.W., Ellis I.O. Prognostic and predictive factors in primary breast cancer and their role in patient management: the Nottingham Breast Team. Eur J Surg Oncol 2001, 27:229-238.
3. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics. CA Cancer J Clin 1997, 47:5-27.
4. U.S. National Institutes of Health 2010, National Cancer Institute. http://www.cancer.gov.
5. Cancer Research UK. 2008. http://info.cancerresearchuk.org.
6. Saez R.A., McGuire W.L., Clark G.M. Prognostic factors in breast cancer. Semin Surg Oncol 1989, 5:102-110.
7. HSr Cody Current surgical management of breast cancer. Curr Opin Obstet Gynecol 2002, 14:45-52.
8. Bedrosian I., Reynolds C., Mick R., Callans L.S., Grant C.S., Donohue J.H., et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 2000, 88:2540-2545.
9. Kuehn T., Bembenek A., Decker T., Sautter-Bihl M.L., Untch M., Wallwiener D., et al. A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance. Cancer 2005, 103:451-461.
10. Chung M.H., Ye W., Giuliano A.E. Role for sentinel lymph node dissection in the management of large (> or = 5 cm) invasive breast cancer. Ann Surg Oncol 2001, 8:688-692.
11. Schwartz G.F. Clinical practice guidelines for the use of axillary sentinel lymph node biopsy in carcinoma of the breast: current update. Breast J 2004, 10:85-88.
12. Lyman G.H., Giuliano A.E., Somerfield M.R., Benson A.B., Bodurka D.C., Burstein H.J., et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005, 23:7703-7720.
13. Specht M.C., Fey J.V., Borgen P.I., HSr Cody Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy?. J Am Coll Surg 2005, 200:10-14.
14. Hodgson N.C., Gulenchyn K.Y. Is there a role for positron emission tomography in breast cancer staging?. J Clin Oncol 2008, 26:712-720.
15. Veronesi U., De Cicco C., Galimberti V.E., Fernandez J.R., Rotmensz N., Viale G., et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007, 18:473-478.
16. Wahl R.L., Siegel B.A., Coleman R.E., Gatsonis C.G. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004, 22:277-285.
17. Weir L., Worsley D., Bernstein V. The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J 2005, 11:204-209.
18. Heusner T.A., Kuemmel S., Hahn S., Koeninger A., Otterbach F., Hamami M.E., et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging 2009, 36:1543-1550.
19. Ueda S., Tsuda H., Asakawa H., Omata J., Fukatsu K., Kondo N., et al. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer 2008, 8:165.
20. Kim J., Lee J., Chang E., Kim S., Suh K., Sul J., et al. Selective sentinel node plus additional non-sentinel node biopsy based on an FDG-PET/CT scan in early breast cancer patients: single institutional experience. World J Surg 2009, 33:943-949.
21. 18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008, 26:4746-4751.
22. Jager J.J., Keymeulen K., Beets-Tan R.G., Hupperets P., van Kroonenburgh M., Houben R., et al. FDG-PET-CT for staging of high-risk breast cancer patients reduces the number of further examinations: a pilot study. Acta Oncol 2010, 49:185-191.
23. Kao C.H., Hsieh J.F., Tsai S.C., Ho Y.J., Yen R.F. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 2000, 20:2189-2192.
24. Eubank W.B., Mankoff D.A., Vesselle H.J., Eary J.F., Schubert E.K., Dunnwald L.K., et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 2002, 22:5-17.
25. Sloka J.S., Hollett P.D., Mathews M. A quantitative review of the use of FDG-PET in the axillary staging of breast cancer. Med Sci Monit 2007, 13:RA37-46.